Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Review, H1 2015

Published: May, 2015 | Pages: 169 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Review, H1 2015', provides an overview of the Adenocarcinoma Of The Gastroesophageal Junction's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Adenocarcinoma Of The Gastroesophageal Junction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Adenocarcinoma Of The Gastroesophageal Junction and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Adenocarcinoma Of The Gastroesophageal Junction
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Adenocarcinoma Of The Gastroesophageal Junction and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Adenocarcinoma Of The Gastroesophageal Junction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Adenocarcinoma Of The Gastroesophageal Junction pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Adenocarcinoma Of The Gastroesophageal Junction
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Adenocarcinoma Of The Gastroesophageal Junction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Adenocarcinoma Of The Gastroesophageal Junction Overview 9
Therapeutics Development 10
Pipeline Products for Adenocarcinoma Of The Gastroesophageal Junction - Overview 10
Pipeline Products for Adenocarcinoma Of The Gastroesophageal Junction - Comparative Analysis 11
Adenocarcinoma Of The Gastroesophageal Junction - Therapeutics under Development by Companies 12
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Adenocarcinoma Of The Gastroesophageal Junction - Products under Development by Companies 17
Adenocarcinoma Of The Gastroesophageal Junction - Companies Involved in Therapeutics Development 19
AB Science 19
Amgen Inc. 20
Apceth GmbH & Co. KG 21
ArQule, Inc. 22
AstraZeneca PLC 23
Boehringer Ingelheim GmbH 24
Boston Biomedical, Inc. 25
Bristol-Myers Squibb Company 26
Cerulean Pharma, Inc. 27
Eli Lilly and Company 28
Epirus Biopharmaceuticals, Inc. 29
F. Hoffmann-La Roche Ltd. 30
Ganymed Pharmaceuticals AG 31
Genentech, Inc. 32
Gilead Sciences, Inc. 33
Mebiopharm Co., Ltd. 34
MedImmune, LLC 35
Merck & Co., Inc. 36
Merck KGaA 37
Millennium Pharmaceuticals, Inc. 38
Novartis AG 39
Panacea Biotec Limited 40
Sanofi 41
Adenocarcinoma Of The Gastroesophageal Junction - Therapeutics Assessment 42
Assessment by Monotherapy Products 42
Assessment by Combination Products 43
Assessment by Target 44
Assessment by Mechanism of Action 47
Assessment by Route of Administration 49
Assessment by Molecule Type 51
Drug Profiles 53
Agenmestencel-T - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
alpelisib - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
AMG-337 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
avelumab - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
AZD-4547 - Drug Profile 59
AZD-4547 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
BI-853520 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
BMS-833923 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
cabazitaxel - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
catumaxomab - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
CRLX-101 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
durvalumab + tremelimumab - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
emibetuzumab - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
erismodegib - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
GS-5745 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
IMAB-362 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
indusatumab vedotin - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
ipatasertib - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
masitinib - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
MBP-426 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
napabucasin - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
panitumumab - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
pembrolizumab - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
ramucirumab - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
solitomab - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
tivantinib - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
trastuzumab biosimilar - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
trastuzumab biosimilar - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
trastuzumab biosimilar - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
trastuzumab emtansine - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
Adenocarcinoma Of The Gastroesophageal Junction - Recent Pipeline Updates 117
Adenocarcinoma Of The Gastroesophageal Junction - Dormant Projects 162
Adenocarcinoma Of The Gastroesophageal Junction - Discontinued Products 163
Adenocarcinoma Of The Gastroesophageal Junction - Product Development Milestones 164
Featured News & Press Releases 164
May 18, 2015: AB Science announces that three clinical abstracts will be presented at the 2015 ASCO annual meeting 164
Jul 22, 2014: Ganymed Completes Recruitment for Randomized Phase 2 FAST Trial of IMAB362 for Gastroesophageal Cancer 166
Jan 23, 2014: apceth's Ground-Breaking First-In-Man, First-In-Class Clinical Trial in Oncology with Genetically Modified Mesenchymal Stromal Cells Is Now Enrolling 166
Appendix 168
Methodology 168
Coverage 168
Secondary Research 168
Primary Research 168
Expert Panel Validation 168
Contact Us 168
Disclaimer 169

List of Tables

Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction, H1 2015 10
Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 12
Number of Products under Development by Companies, H1 2015 (Contd..1) 13
Comparative Analysis by Late Stage Development, H1 2015 14
Comparative Analysis by Clinical Stage Development, H1 2015 15
Comparative Analysis by Early Stage Development, H1 2015 16
Products under Development by Companies, H1 2015 17
Products under Development by Companies, H1 2015 (Contd..1) 18
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by AB Science, H1 2015 19
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Amgen Inc., H1 2015 20
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Apceth GmbH & Co. KG, H1 2015 21
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by ArQule, Inc., H1 2015 22
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by AstraZeneca PLC, H1 2015 23
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Boehringer Ingelheim GmbH, H1 2015 24
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Boston Biomedical, Inc., H1 2015 25
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Bristol-Myers Squibb Company, H1 2015 26
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Cerulean Pharma, Inc., H1 2015 27
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Eli Lilly and Company, H1 2015 28
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015 29
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 30
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Ganymed Pharmaceuticals AG, H1 2015 31
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Genentech, Inc., H1 2015 32
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Gilead Sciences, Inc., H1 2015 33
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Mebiopharm Co., Ltd., H1 2015 34
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by MedImmune, LLC, H1 2015 35
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Merck & Co., Inc., H1 2015 36
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Merck KGaA, H1 2015 37
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 38
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Novartis AG, H1 2015 39
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Panacea Biotec Limited, H1 2015 40
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Sanofi, H1 2015 41
Assessment by Monotherapy Products, H1 2015 42
Assessment by Combination Products, H1 2015 43
Number of Products by Stage and Target, H1 2015 45
Number of Products by Stage and Mechanism of Action, H1 2015 48
Number of Products by Stage and Route of Administration, H1 2015 50
Number of Products by Stage and Molecule Type, H1 2015 52
Adenocarcinoma Of The Gastroesophageal Junction Therapeutics - Recent Pipeline Updates, H1 2015 117
Adenocarcinoma Of The Gastroesophageal Junction - Dormant Projects, H1 2015 162
Adenocarcinoma Of The Gastroesophageal Junction - Discontinued Products, H1 2015 163